NCT04525794已完成不适用
BIOTRONIK- First-in-Human Assessment of the Safety and Clinical Performance of a Sirolimus Derivative-Coated Balloon (BRight DCB) in the Treatment of Subjects With de Novo Lesions in the Superficial Femoral and Proximal Popliteal Artery (BRight First Study)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 10
- 主要终点
- Late Lumen Loss
研究概览
简要总结
The primary aim of this clinical study is to assess the safety and clinical performance of the BRight drug-coated balloon (DCB) in the treatment of lower limb arteries stenosis in subjects with Peripheral Artery Disease (PAD).
The primary endpoint will be Late Lumen Loss (LLL) of the target lesion at 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject has provided written informed consent
- •The subject is willing to participate in the clinical investigation and to comply with the study procedures and follow-up visits
- •Lifestyle-limiting claudication or rest pain requiring treatment of superficial femoral (SFA) and/or proximal popliteal artery (PPA)
- •Rutherford-Becker Clinical Category of 2, 3 or 4
- •Target vessel reference diameter ≥5 mm and ≤ 6 mm (by visual estimation)
- •De novo lesion with >50% stenosis by operator visual estimate within the SFA and/or proximal popliteal arteries in a single limb.
- •Lesion must be located ≥ 1 cm below the Common Femoral Artery (CFA) bifurcation and terminate distally at ≥ 3 cm proximal to the knee joint (radiographic joint space)
- •Single lesion length ≤100 mm for de novo stenotic lesions, or ≤ 70 mm for occluded lesions (one long lesion or multiple serial lesions) by operator visual estimate. Note: Only 1 lesion per patient can be treated. Multiple serial lesions are allowed provided that they can be treated as a single lesion with one balloon.
- •Successful guidewire crossing of lesion.
- •After pre-dilatation, the target lesion is ≤ 30% residual stenosis with no flow limiting dissection and treatable with a single balloon
- •Inflow artery is patent, free from significant lesion stenosis (>50% stenosis considered significant) as confirmed by angiography.
- •Target limb with at least 1 patent (less than 50% stenosis) tibio-peroneal run-off vessel in the target limb confirmed at baseline. (Note: treatment of outflow disease is not permitted.)
排除标准
- •Females who are pregnant, lactating, or intended to become pregnant, or males intending to father children during the study
- •Subject under current medication known to affect CYP3A4 metabolism
- •Contraindication to dual anti-platelet therapy
- •Subject is receiving chronic anticoagulation therapy (e.g. low molecular weight heparin, warfarin, or novel direct oral anticoagulants (N(D)OACs)).
- •Known intolerance to study medications, Limus- like drug or contrast agents that in the opinion of the investigator could not be adequately pretreated
- •Current participation in an investigational drug or another device study
- •History of hemorrhagic stroke within 3 months
- •Patients with a history of Myocardial Infarction (MI) or thrombolysis within 30 days prior-index procedure
- •Previous or planned surgical or interventional procedure within 14 days before or 30 days after index procedure (successful treatment of the ipsilateral and contralateral iliac arteries is permitted prior to enrollment- contralateral iliac artery treatment with no drug eluting technology is allowed during the index procedure)
- •Prior endovascular treatment of the target lesion (e.g., POBA, DCB, BMS, DES, cutting balloons, scoring balloons, cryoplasty, thrombectomy, atherectomy, brachytherapy or laser devices)
- •Previous placement of a bypass graft proximal to the target lesion
- •Chronic renal insufficiency (eGFR < 30 mL/min within 72 hours prior to index procedure)
- •No normal proximal arterial segment in which duplex ultrasound velocity ratios could be measured.
- •Subject is unable to walk without assistance (e.g. walker, cane).
- •Subject is receiving immunosuppressant therapy.
- •Subject has known or suspected active infection at the time of the index procedure.
- •Subject has platelet count < 100,000/mm3 or > 700,000/mm
- •Subject has white blood cell (WBC) count < 3,000/mm
- •Subject is unable to tolerate blood transfusions because of religious beliefs or other reasons.
- •Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the index procedure.
- •Life expectancy less than 12 months due to other comorbidities, that in the investigators opinion, could limit subject ability to comply with the study required follow-up visits/procedure and threaten the study scientific integrity
- •Treatment of the contralateral limb during the same procedure or within 30 days following the study procedure (exclusive of the iliac arteries, which can be treated prior to enrollment or during the index procedure if no drug eluting technology is used)
- •Non femoral vascular access
- •Target lesion would require treatment with more than one balloon
- •Known inadequate distal outflow
- •Acute or sub-acute thrombus in the target vessel
- •Aneurysmal target vessel
- •Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, brachytherapy) during the study procedure in the target lesion or target vessel
- •Presence of concentric calcification that precludes PTA pre-dilatation
- •Significant contralateral or ipsilateral common femoral disease that requires intervention during the index procedure
- •Persistent hemodynamically-significant stenosis following predilatation or residual stenosis of >30%, stent placement, or flow-limiting (Grade D or greater) dissection following pre-dilatation
- •In-stent restenosis
结局指标
主要结局
Late Lumen Loss
时间窗: 6 months post index procedure
Late Lumen Loss, as measure by quantitative vascular angiography (QVA)
次要结局
- Device success(during procedure)
- Acute technical success(during procedure)
- Clinically-driven Target Lesion Revascularization (cd TLR) rate(1, 6 and 12 months post index procedure)
- Clinically-driven Target Vessel Revascularization (cd TVR) rate(1, 6 and 12 months post index procedure)
- Target lesion primary patency(1, 6 and 12 months post index procedure)
- Change in resting target limb Ankle Brachial Index (ABI) as compared to baseline(1, 6 and 12 months post index procedure)
- Major Adverse Event (MAE) rate(1, 6 and 12 months post index procedure)
- All-cause of death rate(1, 6 and 12 months post index procedure)
- Target lesion Binary Restenosis(1, 6 and 12 months post index procedure)
- Acute procedural success(72 hours post index procedure)
- Amputation (minor and major) rate(1, 6 and 12 months post index procedure)
- Change in the Walking Impairment questionnaire (WIQ) as compared to baseline(1, 6 and 12 months post index procedure)
- Embolic event of the index limb(during procedure)
- Change in Rutherford Classification as compared to baseline(1, 6 and 12 months post index procedure)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
不适用
BIOFLOW-INDIA Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in Single de Novo Coronary Artery LesionsCoronary Artery DiseaseNCT01426139Biotronik AG120
已完成
不适用
BIOTRONIK Orsiro Pre-Marketing RegistrationCoronary Artery DiseaseNCT02870985Biotronik (Beijing) Medical Device Ltd.440
进行中（未招募）
2 期
To Study the safety and efficacy of drug releasing Orsiro Cardiac stent in patients with Coronary Artery DiseasesCTRI/2011/07/001928BIOTRONIK AG120
已完成
不适用
IEIK13 For NeurosurgeryOozing (Hemorrhage) During Intracranial ProceduresNCT049539493-D Matrix Europe SAS80
已完成
1 期
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)Purpura, Thrombocytopenic, IdiopathicNCT03275454Bioverativ, a Sanofi company12